Alphamab Oncology (HKG:9966) said JSKN003 received approval from the Center for Drug Evaluation of China's National Medical Products Administration to initiate a phase III clinical study, according to Friday filing with the Hong Kong bourse.
JSKN003 is a HER2-targeting ADC (antibody-drug conjugate) that combines a topoisomerase I inhibitor with KN026 (a humanized anti-HER2 bispecific antibody) used to treat tumors. The drug linker is attached specifically to the antibody's N-glycosylation site using glycoside-specific conjugation, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。